The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease
Open accessAbstract
Aducanumab (Aduhelm) was recently approved by the US Food and Drug Administration (FDA) for the treatment of Alzheimer disease (AD). The approval of aducanumab is controversial. We address why we support this decision and welcome the availability of aducanumab as an important therapy for patients with early AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA has controversially granted accelerated approval to aducanumab and has opined that the reduction of amyloid is reasonably likely to predict clinical benefit 7,9,[98][99][100][101][102][103][104][105][106][107] .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Self-citation
Research works printed but not linked: 1
- Leber P. Guidelines for the clinical evaluation of antidementia drugs. Food and Drug Administration; 1990.
Cited by
Sorted by citations
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Neuropathology of Alzheimer's Disease
Trejo‐Lopez, J. A., Yachnis, A. T., & Prokop, S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01146-y · Cited by 419
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 104
Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 69
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 40
Nanoscale drug formulations for the treatment of Alzheimer's disease progression
Liqin, L., He, H., Du, B., & He, Y. (2025) · RSC Advances · doi:10.1039/d4ra08128e · Cited by 38
Dumurgier, J., Sabia, S., Zetterberg, H., Teunissen, C. E., Hanseeuw, B. J., Orellana, A., Schraen‐Maschke, S., Gabelle, A., Boada, M., Lebouvier, T., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200735 · Cited by 30
Yeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28
Turcu, A. L., Companys-Alemany, J., Phillips, M. B., Patel, D. S., Griñán-Ferré, C., Loza, M. I., Brea, J. M., Pérez, B., Soto, D., Sureda, F. X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114354 · Cited by 27
Amyloid-β42 stimulated hippocampal lactate release is coupled to glutamate uptake
Hascup, E., Sime, L. N., Peck, M. R., & Hascup, K. (2021) · Scientific Reports · doi:10.1038/s41598-022-06637-2 · Cited by 20
Clinical Efficacy, Drug Safety, and Surrogate Endpoints
Hershey, L. A., & Tarawneh, R. M. (2021) · Neurology · doi:10.1212/wnl.0000000000012453 · Cited by 21
Bernardo, A. M., Marcotte, M. D., Wong, K. D., Sharmin, D., Pandey, K. P., Cook, J. M., Sibille, E. L., & Prévot, T. D. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.12.001 · Cited by 15
α-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?
Seibyl, J. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263918 · Cited by 13
Practical Considerations in the Administration of Aducanumab for the Neurologist
Coerver, K. A., Yu, M. M., D’Abreu, A., Wasserman, M., & Nair, K. V. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001144 · Cited by 10
Hasan, M. F., & Trushina, E. V. (2022) · Brain Sciences · doi:10.3390/brainsci12050552 · Cited by 10
Fasina, O. B., Li, L., Chen, D., Yi, M., Xiang, L., & Qi, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111719 · Cited by 9
Are we ready to use anti-amyloid therapy in Alzheimer's disease?
Brucki, S. M. D., César‐Freitas, K. G., Spera, R. R., Borges, C. R., & Smid, J. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s117 · Cited by 8
Therapeutic nanosweepers promote β-amyloid removal from the brain for Alzheimer's disease treatment
Xu, H., Zhao, Y., Qi, Y., Xue, X., & Liu, Y. (2022) · Biomaterials Science · doi:10.1039/d2bm01319c · Cited by 7
Yin, G., Chen, X., Tang, Y., Xiao, R., Dou, C., Wang, H., Lu, Q., Li, C., Du, F., & Yin, P. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138659 · Cited by 6
Yiğit, V., Kalender, S., & ÇETİNTÜRK, İ. (2023) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-023-00463-7 · Cited by 4
Fidan, G. S., Parlar, S., Tarikogullari, A. H., Alptüzün, V., & Alpan, A. S. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200152 · Cited by 4
Napoli, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097996 · Cited by 4
Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer’s Disease
Seo, Y., Jang, H., & Lee, H. (2022) · Life · doi:10.3390/life12020275 · Cited by 1
Lyu, H., Ye, Y., Lui, V. C. H., & Wang, B. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110901 · Cited by 1
A new neuroprotective candidate TJ1 targeting amyloidogenesis in 5xFAD Alzheimer’s disease mice
Deng, J., Huang, L.-F., Bian, Z.-Y., Feng, X.-Y., Qi, R.-Y., Dong, W.-X., Gao, J., & Tang, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112653 · Cited by 1
Bernardo, A. M., Marcotte, M. D., Wong, K. D., Sharmin, D., Pandey, K. P., Cook, J. M., Sibille, E. L., & Prévot, T. D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.30.510361 · Cited by 1
Sandrock, A. W. (2021) · Annals of Neurology · doi:10.1002/ana.26254
Calculating efficacy of new ophthalmic treatments. The new calculus
Novack, G. D. (2021) · The Ocular Surface · doi:10.1016/j.jtos.2021.11.008
Eyes on New Product Development
Novack, G. D. (2021) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2021.29086.gdn
Expedited regulatory product approval in the time of COVID-19
Novack, G. D. (2022) · The Ocular Surface · doi:10.1016/j.jtos.2022.05.007
Yiğit, V., Kalender, S., & ÇETİNTÜRK, İ. (2024) · Figshare · doi:10.6084/m9.figshare.26609403
Metadata
- Authors
- Salloway, S., & Cummings, J.
- Affiliations
- University of Nevada, Las Vegas (US)
- Venue
- Neurology
- Published
- 2021-09-14
- Volume
- 97
- Issue
- 11
- Pages
- 543-544
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC8456361
- OpenAlex
- W3178304290
- Cited by
- 34
- References
- 1
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 4 · 2022: 16 · 2021: 7
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- Sunovion
- Eisai (P20GM109025)
- Novo Nordisk
- Grifols
- Genentech (P20GM109025)
- National Institute on Aging (R01AG053798, P20AG068053, R35AG71476, P30AG072980)
- National Institute of General Medical Sciences (NIA R35AG71476, P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- aducanumab, Alzheimer's disease, anti-amyloid therapy, FDA drug approval, early Alzheimer's disease, anti-amyloid monoclonal antibodies
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
